cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.10048364
title: Table S1 from Intraspecific male combat behaviour predicts morphology of cervical vertebrae in ruminant mammals

description: Specimen numbers for all male and female specimens of each species included in this study, sex-specific mean body mass for males and females (from Supplemental Reference 24), fighting style category, and references for fighting style designation (see Supplemental References).
DOI: 10.6084/m9.figshare.10048367
title: Male morphometric data from Intraspecific male combat behaviour predicts morphology of cervical vertebrae in ruminant mammals

description: csv file with log-transformed measurements for all variables, as well as body size and fighting style (input for PGLS analyses)
DOI: 10.6084/m9.figshare.10048361
title: Female morphometric data from Intraspecific male combat behaviour predicts morphology of cervical vertebrae in ruminant mammals

description: csv file with log-transformed measurements for all variables, as well as body size and fighting style (input for PGLS analyses)
DOI: 10.6084/m9.figshare.10048364.v1
title: Table S1 from Intraspecific male combat behaviour predicts morphology of cervical vertebrae in ruminant mammals

description: Specimen numbers for all male and female specimens of each species included in this study, sex-specific mean body mass for males and females (from Supplemental Reference 24), fighting style category, and references for fighting style designation (see Supplemental References).
DOI: 10.6084/m9.figshare.10048358
title: Table S2 from Intraspecific male combat behaviour predicts morphology of cervical vertebrae in ruminant mammals

description: Results of PGLS analyses of female vertebral measurements on female body mass + female weapon presence/absence.
DOI: 10.6084/m9.figshare.10048367.v1
title: Male morphometric data from Intraspecific male combat behaviour predicts morphology of cervical vertebrae in ruminant mammals

description: csv file with log-transformed measurements for all variables, as well as body size and fighting style (input for PGLS analyses)
DOI: 10.6084/m9.figshare.10048349
title: Data from PeerJ Submission: How do forested wetland plant community and species distributions relate to flooding stress? A case from a palustrine forested wetland, Washington State, USA.

description: Data from PeerJ Submission: How do forested wetland plant community and species distributions relate to flooding stress? A case from a palustrine forested wetland, Washington State, USA.<br>CSV Data of: <br>overstory vegetation, understory vegetation, and overstory indicator values<br><br>See associated metadata file.
DOI: 10.6084/m9.figshare.10048361.v1
title: Female morphometric data from Intraspecific male combat behaviour predicts morphology of cervical vertebrae in ruminant mammals

description: csv file with log-transformed measurements for all variables, as well as body size and fighting style (input for PGLS analyses)
DOI: 10.6084/m9.figshare.10048346
title: Supplementary Material for: Placebo Effects of Nurses’ Communication alongside Standard Medical Care on Pain and Other Outcomes: A Randomized Controlled Trial in Clinical Tonsillectomy Care

description: Medicine
DOI: 10.6084/m9.figshare.10048340
title: Supplementary Material for: Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia

description: Managing acute myeloid leukemia (AML) is often hampered by repeated failure to achieve complete remission as well as recurrent relapse that causes an emergent need for alternative salvage therapies. The efficacy of most salvage therapies is based on anthracycline combinations. In highly pretreated patients who are not eligible for anthracycline-based protocols therapeutic alternatives are limited. For this particular group we evaluated the efficacy and safety of fludarabine, cytarabine, granulocyte colony-stimulating factor (FLAG) in combination with etoposide (FLAG-Eto) in 36 patients. The complete remission rate (CR) was 25.7% with a median overall survival of 6 months (95% CI 4.5–7.7). The median disease-free survival for CR/CRi/MLFS (CR/CR with incomplete he­matological recovery/morphologic leukemia-free state) patients was 8 months (95% CI 0.6–15.5). The mortality rate on day 30 was 8% and increased on day 60 to 17%. Our results show meaningful anti-leukemic activity of the FLAG-Eto regimen with a moderate toxicity profile in heavily pretreated relapsed/refractory AML patients enabling consolidating allogeneic stem cell transplantation.
DOI: 10.6084/m9.figshare.10048340.v1
title: Supplementary Material for: Etoposide Combined with FLAG Salvage Therapy Is Effective in Multiple Relapsed/Refractory Acute Myeloid leukemia

description: Managing acute myeloid leukemia (AML) is often hampered by repeated failure to achieve complete remission as well as recurrent relapse that causes an emergent need for alternative salvage therapies. The efficacy of most salvage therapies is based on anthracycline combinations. In highly pretreated patients who are not eligible for anthracycline-based protocols therapeutic alternatives are limited. For this particular group we evaluated the efficacy and safety of fludarabine, cytarabine, granulocyte colony-stimulating factor (FLAG) in combination with etoposide (FLAG-Eto) in 36 patients. The complete remission rate (CR) was 25.7% with a median overall survival of 6 months (95% CI 4.5–7.7). The median disease-free survival for CR/CRi/MLFS (CR/CR with incomplete he­matological recovery/morphologic leukemia-free state) patients was 8 months (95% CI 0.6–15.5). The mortality rate on day 30 was 8% and increased on day 60 to 17%. Our results show meaningful anti-leukemic activity of the FLAG-Eto regimen with a moderate toxicity profile in heavily pretreated relapsed/refractory AML patients enabling consolidating allogeneic stem cell transplantation.
DOI: 10.6084/m9.figshare.10048214
title: Supplementary Material for: Percutaneous Coronary Intervention Does Not Lower Cardiovascular Outcomes in Patients with Chronic Kidney Disease

description: <b><i>Background:</i></b> Chronic kidney disease (CKD) is associated with an increased risk of adverse cardiovascular outcomes, in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). However, most studies used bare-metal stents or first-generation drug-eluting stents, and less guideline-directed therapy to reduce cardiovascular risk was reported in CKD patients. This study investigates the impact of moderate-CKD on patients undergoing PCI in the current era. <b><i>Methods:</i></b> Patient level data were pooled from 2 multicenter randomized trials (BIONICS and NIREUS trials) with a near “all-comers” design, comparing PCI with ridaforolimus-eluting stents vs. zotarolimus-eluting stents in patients with CAD. Patients were classified according to the presence or absence of moderate-CKD, defined as creatinine clearance (CrCl) &lt;60 mL/min. We compared baseline characteristics, angiographic findings, and clinical outcomes 1-year post-PCI. <b><i>Results:</i></b> 236/2,201 (10.7%) patients had CKD, mean CrCl of 50.3 + 7.8 mL/min. These patients were generally older and more often with hypertension than non-CKD patients, but the use of guideline-directed therapy was similar between the groups. CKD was associated with an increased risk of cardiovascular death (hazard ratio [HR] 6.08; 95% CI 2.11–17.51; <i>p</i> &lt; 0.001), but with a reduced occurrence of repeated revascularization, including ischemia-driven revascularization (HR 0.47; 95% CI 0.24–0.92; <i>p</i> &lt; 0.05). The rate of repeated angiography per severe cardiovascular adverse event was significantly lower in the CKD than the non-CKD group (23/38 [61%] vs. 253/334 [76%], <i>p</i> &lt; 0.05). <b><i>Conclusions:</i></b> Moderate-CKD in patients with CAD was associated with higher rates of all-cause and cardiovascular mortality, yet with a lower risk of revascularization 1-year following PCI. Lack of guideline-directed medical therapy does not explain the adverse outcome of CKD patients.
DOI: 10.6084/m9.figshare.10048217
title: Data fledging success

description: Data on fledging success from San-Jose et al., "Differential fitness effects of moonlight on plumage colour morphs in barn owls." https://doi.org/10.1038/s41559-019-0967-2
DOI: 10.6084/m9.figshare.10048262
title: Data on breeding time and moonlight

description: Data on moonlight conditions at different times of breeding from San-Jose et al., "Differential fitness effects of moonlight on plumage colour morphs in barn owls." https://doi.org/10.1038/s41559-019-0967-2
DOI: 10.6084/m9.figshare.10048208
title: Data nestling body mass

description: Data on nestling body mass from San-Jose et al., "Differential fitness effects of moonlight on plumage colour morphs in barn owls." https://doi.org/10.1038/s41559-019-0967-2
DOI: 10.6084/m9.figshare.10048214.v1
title: Supplementary Material for: Percutaneous Coronary Intervention Does Not Lower Cardiovascular Outcomes in Patients with Chronic Kidney Disease

description: <b><i>Background:</i></b> Chronic kidney disease (CKD) is associated with an increased risk of adverse cardiovascular outcomes, in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). However, most studies used bare-metal stents or first-generation drug-eluting stents, and less guideline-directed therapy to reduce cardiovascular risk was reported in CKD patients. This study investigates the impact of moderate-CKD on patients undergoing PCI in the current era. <b><i>Methods:</i></b> Patient level data were pooled from 2 multicenter randomized trials (BIONICS and NIREUS trials) with a near “all-comers” design, comparing PCI with ridaforolimus-eluting stents vs. zotarolimus-eluting stents in patients with CAD. Patients were classified according to the presence or absence of moderate-CKD, defined as creatinine clearance (CrCl) &lt;60 mL/min. We compared baseline characteristics, angiographic findings, and clinical outcomes 1-year post-PCI. <b><i>Results:</i></b> 236/2,201 (10.7%) patients had CKD, mean CrCl of 50.3 + 7.8 mL/min. These patients were generally older and more often with hypertension than non-CKD patients, but the use of guideline-directed therapy was similar between the groups. CKD was associated with an increased risk of cardiovascular death (hazard ratio [HR] 6.08; 95% CI 2.11–17.51; <i>p</i> &lt; 0.001), but with a reduced occurrence of repeated revascularization, including ischemia-driven revascularization (HR 0.47; 95% CI 0.24–0.92; <i>p</i> &lt; 0.05). The rate of repeated angiography per severe cardiovascular adverse event was significantly lower in the CKD than the non-CKD group (23/38 [61%] vs. 253/334 [76%], <i>p</i> &lt; 0.05). <b><i>Conclusions:</i></b> Moderate-CKD in patients with CAD was associated with higher rates of all-cause and cardiovascular mortality, yet with a lower risk of revascularization 1-year following PCI. Lack of guideline-directed medical therapy does not explain the adverse outcome of CKD patients.
DOI: 10.6084/m9.figshare.10048217.v1
title: Data fledging success

description: Data on fledging success from San-Jose et al., "Differential fitness effects of moonlight on plumage colour morphs in barn owls." https://doi.org/10.1038/s41559-019-0967-2
DOI: 10.6084/m9.figshare.10048205
title: Investigation of biochemical and physiological parameters of the newborn Saiga antelope (Saiga tatarica) in Gansu Province, China

description: This data set consists of two sections, Biochemical and Physiological Parameters. This data was collected from the Newborn Saiga antelope living in the Gansu Province of China. This data was restricted until the manuscript was accepted for publication due to the special and endangered animal used in the research studies. All researchers in the scope of this research are free to view the data and use it for research purposes. <br>
DOI: 10.6084/m9.figshare.10048208.v1
title: Data nestling body mass

description: Data on nestling body mass from San-Jose et al., "Differential fitness effects of moonlight on plumage colour morphs in barn owls." https://doi.org/10.1038/s41559-019-0967-2
DOI: 10.6084/m9.figshare.10048187
title: Data voles freezing time

description: Data on vole freezing time from San-Jose et al., "Differential fitness effects of moonlight on plumage colour morphs in barn owls." https://doi.org/10.1038/s41559-019-0967-2
DOI: 10.6084/m9.figshare.10048196
title: Supplementary Material for: Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

description: <b><i>Background:</i></b> Among diabetics, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality, and progression of their underlying disease. Finerenone is a novel, non-steroidal, selective mineralocorticoid-receptor antagonist which has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD), while revealing only a low risk of hyperkalemia. However, the effect of finerenone on renal and CV outcomes has not been investigated in long-term trials yet. <b><i>Methods:</i></b> The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease ­(FIDELIO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important renal and CV outcomes in T2D patients with CKD. FIDELIO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 5.5 years. FIDELIO-DKD randomized 5,734 patients with an estimated glomerular filtration rate (eGFR) ≥25–&lt;75 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30–≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death. <b><i>Conclusion:</i></b> FIDELIO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of renal and CV events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
DOI: 10.6084/m9.figshare.10048187.v1
title: Data voles freezing time

description: Data on vole freezing time from San-Jose et al., "Differential fitness effects of moonlight on plumage colour morphs in barn owls." https://doi.org/10.1038/s41559-019-0967-2
DOI: 10.6084/m9.figshare.10048157
title: Data Vole Response

description: Data on voles' reponse to barn owl decoys from San-Jose et al., "Differential fitness effects of moonlight on plumage colour morphs in barn owls." https://doi.org/10.1038/s41559-019-0967-2
DOI: 10.6084/m9.figshare.10048157.v1
title: Data Vole Response

description: Data on voles' reponse to barn owl decoys from San-Jose et al., "Differential fitness effects of moonlight on plumage colour morphs in barn owls." https://doi.org/10.1038/s41559-019-0967-2
DOI: 10.6084/m9.figshare.10048091
title: Data Hunting Success

description: Data on hunting success from San-Jose et al., "Differential fitness effects of moonlight on plumage colour morphs in barn owls." https://doi.org/10.1038/s41559-019-0967-2
DOI: 10.6084/m9.figshare.10048136
title: Supplementary Material for: Congenital Nephrotic Syndrome in India in the Current Era: A Multicenter Case Series

description: <b><i>Background:</i></b> There is a paucity of information on epidemiology, diagnosis, and treatment outcomes of congenital nephrotic syndrome (CNS) in developing countries. <b><i>Methods:</i></b> Retrospective (2012–2017) review of case records undertaken across 12 Indian pediatric nephrology centers. <b><i>Results:</i></b> Sixty-five children (58% male, median birth weight 2.4 kg [interquartile range (IQR) 2.1–2.86]) were identified with CNS. Nearly half (45%) were preterm with previous history of fetal loss/sibling death in 22% and history of consanguinity in a third. No infective etiology was confirmed. Genetic reports available for 15 (23%) children identified causal mutations in 10 (8 in NPHS1 [1 novel variant], 1 in WT 1 [novel variant], and 1 in PLCE-1 gene). In addition, 1 child was clinically diagnosed as Galloway Mowat syndrome. Next-generation sequencing showed 80% yield and Sanger sequencing 20%. Albumin infusion and angiotensin-converting enzyme inhibitors were used initially in around two-third of cohort, while only 12% of children received indomethacin. Totally, 22 (34%) children were lost to follow-up after initial visit, and among the rest median follow-up was 69 days (IQR 20–180) with 18 (42%) deaths. Eight children showed partial response (including 2 with NPHS1 compound mutation), 1 complete response, and all of them were alive at last follow-up in contrast to 53% mortality among nonresponders, <i>p</i> = 0.004. <b><i>Conclusion:</i></b> This largest reported series on CNS from India revealed suboptimal management with poor outcome as well as low number of CNS being subjected to genetic evaluation.
DOI: 10.6084/m9.figshare.10048082
title: Data Food Provisioning

description: Data on food provisioning from San-Jose et al., "Differential fitness effects of moonlight on plumage colour morphs in barn owls." https://doi.org/10.1038/s41559-019-0967-2
DOI: 10.6084/m9.figshare.10048091.v1
title: Data Hunting Success

description: Data on hunting success from San-Jose et al., "Differential fitness effects of moonlight on plumage colour morphs in barn owls." https://doi.org/10.1038/s41559-019-0967-2
DOI: 10.6084/m9.figshare.10048196.v1
title: Supplementary Material for: Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

description: <b><i>Background:</i></b> Among diabetics, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality, and progression of their underlying disease. Finerenone is a novel, non-steroidal, selective mineralocorticoid-receptor antagonist which has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD), while revealing only a low risk of hyperkalemia. However, the effect of finerenone on renal and CV outcomes has not been investigated in long-term trials yet. <b><i>Methods:</i></b> The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease ­(FIDELIO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important renal and CV outcomes in T2D patients with CKD. FIDELIO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 5.5 years. FIDELIO-DKD randomized 5,734 patients with an estimated glomerular filtration rate (eGFR) ≥25–&lt;75 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30–≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death. <b><i>Conclusion:</i></b> FIDELIO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of renal and CV events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
DOI: 10.6084/m9.figshare.10048136.v1
title: Supplementary Material for: Congenital Nephrotic Syndrome in India in the Current Era: A Multicenter Case Series

description: <b><i>Background:</i></b> There is a paucity of information on epidemiology, diagnosis, and treatment outcomes of congenital nephrotic syndrome (CNS) in developing countries. <b><i>Methods:</i></b> Retrospective (2012–2017) review of case records undertaken across 12 Indian pediatric nephrology centers. <b><i>Results:</i></b> Sixty-five children (58% male, median birth weight 2.4 kg [interquartile range (IQR) 2.1–2.86]) were identified with CNS. Nearly half (45%) were preterm with previous history of fetal loss/sibling death in 22% and history of consanguinity in a third. No infective etiology was confirmed. Genetic reports available for 15 (23%) children identified causal mutations in 10 (8 in NPHS1 [1 novel variant], 1 in WT 1 [novel variant], and 1 in PLCE-1 gene). In addition, 1 child was clinically diagnosed as Galloway Mowat syndrome. Next-generation sequencing showed 80% yield and Sanger sequencing 20%. Albumin infusion and angiotensin-converting enzyme inhibitors were used initially in around two-third of cohort, while only 12% of children received indomethacin. Totally, 22 (34%) children were lost to follow-up after initial visit, and among the rest median follow-up was 69 days (IQR 20–180) with 18 (42%) deaths. Eight children showed partial response (including 2 with NPHS1 compound mutation), 1 complete response, and all of them were alive at last follow-up in contrast to 53% mortality among nonresponders, <i>p</i> = 0.004. <b><i>Conclusion:</i></b> This largest reported series on CNS from India revealed suboptimal management with poor outcome as well as low number of CNS being subjected to genetic evaluation.
DOI: 10.6084/m9.figshare.10048082.v1
title: Data Food Provisioning

description: Data on food provisioning from San-Jose et al., "Differential fitness effects of moonlight on plumage colour morphs in barn owls." https://doi.org/10.1038/s41559-019-0967-2
DOI: 10.6084/m9.figshare.10048055
title: code

description: Code to analyze the datasets in this project
DOI: 10.6084/m9.figshare.10048196.v2
title: Supplementary Material for: Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

description: <b><i>Background:</i></b> Among diabetics, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality, and progression of their underlying disease. Finerenone is a novel, non-steroidal, selective mineralocorticoid-receptor antagonist which has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD), while revealing only a low risk of hyperkalemia. However, the effect of finerenone on renal and CV outcomes has not been investigated in long-term trials yet. <b><i>Methods:</i></b> The Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease ­(FIDELIO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important renal and CV outcomes in T2D patients with CKD. FIDELIO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 5.5 years. FIDELIO-DKD randomized 5,734 patients with an estimated glomerular filtration rate (eGFR) ≥25–&lt;75 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30–≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death. <b><i>Conclusion:</i></b> FIDELIO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of renal and CV events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen.
DOI: 10.6084/m9.figshare.10048031
title: list of 216 species relevant to correct IDs

description: List of 216 species relevant to correct IDs and some useful attributes of each
DOI: 10.6084/m9.figshare.10048028
title: snapp-image-metadata-mistakes.csv

description: Image metadata with mistakes fixed and documented